Study on the Safety and Effects of THOR-707 in Adults with Advanced or Metastatic Solid Tumors

Inclusion Criteria

• Have a measurable tumor that can be tracked using standard criteria.
• Have a life expectancy of at least 12 weeks.
• For certain parts of the study, participants should not have previously received PD-1 inhibitors, unless discussed with the study team.
• Be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate heart, blood, liver, and kidney function.
• Have a confirmed diagnosis of advanced or metastatic solid tumors with at least one tumor that can be safely biopsied.
• For specific groups, have certain types of cancer or previous treatments as outlined by the study.
• Have no standard treatment options available, or have refused or not tolerated standard treatments.
• Women of childbearing potential and men must agree to use effective birth control during the study and for a specified time after the last dose.
• Women must have a negative pregnancy test before starting treatment.
• Men must agree not to donate sperm during the study and for a specified time after the last dose.
• In Spain, Chile, and Argentina, only certain groups will be open for enrollment.

Exclusion Criteria

• Have received radiation therapy or certain cancer treatments within a specified time before starting the study drug.
• Have had severe side effects from previous cancer treatments.
• Have had major surgery recently or need major surgery during the study.
• Have active autoimmune diseases requiring treatment or a history of severe autoimmune diseases.
• Have untreated or active brain cancer unless stable and not requiring certain medications.
• Have lung issues or require oxygen therapy.
• Have had recent infections requiring antibiotics.
• Have a history of organ transplants.
• Have uncontrolled diabetes or other immune-related conditions.
• Have active infections like HIV or hepatitis C.
• Have uncontrolled hepatitis B unless treated and stable.
• Have received a live vaccine recently.
• Have had significant bleeding or blood clots recently.
• Have severe heart conditions or uncontrolled high blood pressure.
• Have allergies to components of the study drug.
• Have another active cancer or a history of cancer that affects study assessments.
• Have any serious medical or psychiatric conditions that would interfere with the study.
• Are pregnant, breastfeeding, or planning to conceive during the study.
• Are participating in another clinical trial with a treatment component.
• For certain groups, have specific eye conditions or low oxygen levels.
• For specific groups, have certain types of melanoma.